<DOC>
	<DOCNO>NCT01405560</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy vaniprevir ( 300 mg twice daily ) give combination pegylated interferon alfa-2b ( peg-IFN ) ribavirin ( RBV ) Japanese participant chronic hepatitis C ( CHC ) genotype ( GT ) 1 respond previous treatment . The primary efficacy objective estimate efficacy vaniprevir , peg-IFN RBV 24 week assess percentage participant achieve undetectable Hepatitis C Virus ribonucleic acid ( HCV RNA ) 24 week completion study therapy ( Sustained Viral Response 24 [ SVR24 ] ) .</brief_summary>
	<brief_title>Vaniprevir Plus PegIntron®/Ribavirin Japanese Participants With Chronic Hepatitis C Who Are Non-responders Previous Treatment ( MK-7009-045 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion criterion : Japanese participant diagnose compensate CHC GT 1 Absence ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom advance liver disease Has receive tolerate treatment IFNbased therapy ( IFN α , IFN β , pegIFN ) without use ribavirin , fail respond prior treatment ( partial responder null responder ) No evidence cirrhosis Exclusion criterion : Coinfection human immunodeficiency virus ( HIV ) Positive hepatitis B surface antigen evidence active hepatitis B infection Any condition contraindicate caution require treatment pegIFN RBV Any condition prestudy laboratory abnormality , history illness , , opinion investigator , might confound result study pose additional risk administer study drug , pegIFN RBV , participant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>